Zobrazeno 1 - 10
of 65
pro vyhledávání: '"E B, Silberstein"'
Autor:
Clinton H. Joiner, Donald L. Rucknagel, G Mayfield-Pratt, Robert S. Franco, Mary B. Palascak, Murray Weiner, T A Nemeth, E B Silberstein, J Lohmann
Publikováno v:
Journal of Clinical Investigation. 101:2730-2740
Sickle red blood cells (RBC) are subject to a number of important cellular changes and selection pressures. In this study, we validated a biotin RBC label by comparison to the standard 51Cr label, and used it to study changes that occur in sickle cel
Autor:
E. B. Silberstein
Publikováno v:
Clinical Nuclear Medicine ISBN: 9783540280255
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f55e9906d6a018bed37bba32af5d77da
https://doi.org/10.1007/978-3-540-28026-2_15
https://doi.org/10.1007/978-3-540-28026-2_15
Publikováno v:
Oncology (Williston Park, N.Y.). 15(2)
Although bone pain from osteoblastic metastases can be ameliorated 50% to 80% of the time by use of intravenously or orally administered radiopharmaceuticals, we cannot accurately predict who will or will not respond. The radiopharmaceuticals contain
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(11)
The Code of Federal Regulations, title 10, part 35.75 (10CFR35.75), provides greater latitude and flexibility in the dosing and management of outpatients treated with therapeutic 131I than did preceding regulations. Prescribing physicians should cons
Autor:
E B, Silberstein
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 39(12)
This study was undertaken to determine the prevalence of adverse reactions to positron emitting radiopharmaceuticals as well as to nonradioactive drugs used in interventional nuclear medicine during PET studies.A prospective 4-yr study was performed
Autor:
E B, Silberstein
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 39(10)
Autor:
S C, Srivastava, H L, Atkins, G T, Krishnamurthy, I, Zanzi, E B, Silberstein, G, Meinken, L F, Mausner, F, Swailem, T, D'Alessandro, C J, Cabahug, Y, Lau, T, Park, S, Madajewicz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(1)
The physical characteristics of Sn-117m combined with the biodistribution of the compound tin-117m (Stannic, 4+) diethylenetriaminepentaacetic acid (Sn-117m DTPA) suggest that it should be an excellent agent for the palliation of pain from bony metas
Autor:
E. B. Silberstein
Publikováno v:
Clinical Nuclear Medicine ISBN: 9780412751806
This chapter describes the use of beta- or electron-emitting radiopharmaceuticals for treating several painful musculoskeletal conditions. These radiopharmaceuticals emit negatively charged particles (beta particles or electrons) with a maximum range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::935ba216683af0af9ed987e231711133
https://doi.org/10.1007/978-1-4899-3356-0_1
https://doi.org/10.1007/978-1-4899-3356-0_1
Autor:
S P, Bartold, K J, Donohoe, J W, Fletcher, T P, Haynie, R E, Henkin, E B, Silberstein, H D, Royal, A, Van den Abbeele
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 38(6)
Publikováno v:
Cleveland Clinic journal of medicine. 63(1)
SUMMARY It is recommended that routine bone scans not be adopted for follow-up of patients with stage I—II breast cancer. Bone scintigraphy should be reserved for evaluation of patients presenting with symptoms suggestive of bone metastases.